欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
According to the revised draft chapter 5 – Production – of the EU GMP Guide from January 2013, the selection, qualification, approval and maintenance of suppliers has to be documented and the level of control has to be proportionate to the potential risks posed by the individual materials. Manufacturers of medicinal products are responsible for testing the starting and packaging materials as described in the marketing authorisation dossier. However, it is explicitly accepted to utilise partial or full test analysis results for a material from an approved manufacturer, if the following requirements are fulfilled: a) A formal agreement including the transport conditions to ensure the maintenance of the quality characteristics of the starting materials b) Regularly performed audits at the production sites c) A certificate of analysis signed by a designated person with appropriate qualifications and experience d) Significant experience in dealing with the starting material manufacturer (“history of compliance”) e) Full analyses that are performed regularly by the medicinal product manufacturer to compare the results with the supplier’s certificate of analysis. The deadline for comments to the revised EU GMP Guide Chapter 5 was 18 July 2013. The deadline for coming into operation will be 6 months after the publication of the final chapter 6.
EU-GMP将要修订第5个章节-生产部分,对于起始物料、包装材料的检测可以减少测试项目,并明确规定必须符合以下要求:
a)正式的协议,包括运输条件。保证起始物料的质量特性的稳定维持
b)供应商的定期现场审计
c)COA,由指定的有资质和经验的人员颁发
d)与供应商厂家的主要合作经验(历史符合性)
e)定期进行全检并与供应商的COA进行对比
|